PFE - Pyxis starts dosing in early stage study of cancer therapy PYX-201

2023-03-16 08:17:07 ET

• Pyxis Oncology ( NASDAQ: PYXS ) said the first person was dosed in a phase 1 trial of PYX-201 for solid tumors.
• PYX-201 is a novel antibody-drug conjugate (ADC), which was licensed from Pfizer ( PFE ), targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen, which is a component of the extracellular matrix in tumors. EDB fibronectin is overexpressed in several solid tumors and minimally expressed in most normal adult tissues, Pyxis added.
• The company expects preliminary data from the study in early 2024.
• "PYX-201 has the potential to offer a new approach to targeting multiple tumor types via a multipronged mechanism of action that may benefit patients with solid tumors," said President and CEO Lara Sullivan.

For further details see: